Chapter 24: Red Flags: When to Reevaluate

The discussion encompasses recognition of treatment failure through persistent symptom severity, unexpected symptom recurrence despite ongoing medication use, and management of adverse effects that compromise therapeutic benefit or patient adherence. A central focus involves determining appropriate duration of pharmacological intervention across different psychiatric conditions, with distinct timelines for major depression, anxiety disorders, posttraumatic stress disorder, obsessive-compulsive disorder, and bipolar spectrum conditions following symptom stabilization. The chapter integrates pediatric considerations as a critical treatment variable, examining developmental factors that differentiate medication appropriateness in children and adolescents from adult populations and establishing clinical guidelines for when psychopharmacological intervention becomes necessary versus when behavioral interventions should remain primary. Discontinuation protocols receive detailed attention, establishing the clinical importance of gradual tapering rather than abrupt cessation to minimize withdrawal phenomena and relapse vulnerability. The content examines multiple factors contributing to treatment failure and relapse risk, including medication tolerance development, altered metabolic processing, concurrent medical conditions affecting drug efficacy, and patient compliance patterns. Throughout the chapter, clinicians learn to integrate pharmacological knowledge with clinical observation skills to identify when current treatment approaches require modification, when medication changes warrant consideration, and when alternative therapeutic strategies may prove more beneficial. This framework enables practitioners to move beyond initial medication selection toward dynamic treatment management that responds to individual patient trajectories and emerging clinical presentations across the lifespan.